FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285619> ?p ?o ?g. }

• W4379285619 endingPage "TPS1132" @default.
• W4379285619 startingPage "TPS1132" @default.
• W4379285619 abstract "TPS1132 Background: A potent PARP inhibitor, talazoparib, demonstrated superior clinical activity compared to standard chemotherapy in germline BRCA1/2-mutant advanced breast cancer patients. However, the role of talazoparib treatment in BRCA1/2 wild-type triple-negative breast cancer (TNBC) patients remains undefined, although high incidence of homologous recombination deficiency (HRD) is one of the major characteristics of the TNBC. Previous studies indicated clinical responsiveness to platinum agents is a useful surrogate for HRD that may predict favorable PARP inhibitor response. Here, we present a phase II study to test talazoparib maintenance therapy in germline BRCA1/2 mutation unselected advanced TNBC patients after platinum-based chemotherapy. Methods: The KCSG BR21-10 study (NCT04755868) is a randomized double-blind placebo-controlled phase II clinical trial of talazoparib maintenance therapy in metastatic TNBC patients whose tumor showed platinum-sensitivity to first- or second-line platinum-based chemotherapy. The criteria for platinum-sensitivity were set as follows: remaining complete response (CR), partial response (PR), or stable disease (SD) after 6 to 9 tri-weekly doses or 18 to 27 weekly doses of platinum-based chemotherapy. The eligible TNBC patients are enrolled to the trial after completion of platinum-based therapy and 1:1 randomized to receive talazoparib (once daily 1.0 mg) or placebo maintenance therapy. The patient with any germline BRCA1/2 mutation status is eligible, and randomization stratification factors include line of platinum-based chemotherapy, response to platinum-based chemotherapy, and germline BRCA1/2 mutation status. The talazoparib/placebo maintenance treatment is initiated within 8 weeks after the last platinum chemotherapy. At the time of progression of disease, unblinding can be performed and patients in placebo arm may be eligible for crossover to talazoparib single treatment. The primary endpoint is progression-free survival (PFS) after randomization by RECIST 1.1, and the key secondary endpoints are overall survival, PFS2, objective response rate, adverse events by CTCAE 5.0 criteria, and quality of life. We also planned exploratory study to find predictive biomarker by tumor tissue and blood analysis. The median PFS from the randomization is expected to be 3 months in the placebo maintenance arm and we expect that talazoparib maintenance will improve PFS with hazard ratio of 0.65. It is predicted that a total of 206 patients (103 patients in each arm) are required with the α of 0.05 and power of 0.8 (1-β) by two-sided test, considering monthly 3% dropout rate. Currently, 23 of planned 206 patients have been enrolled. Clinical trial information: NCT04755868 ." @default.
• W4379285619 created "2023-06-05" @default.
• W4379285619 creator A5013612802 @default.
• W4379285619 creator A5019945009 @default.
• W4379285619 creator A5021046796 @default.
• W4379285619 creator A5023107984 @default.
• W4379285619 creator A5025054615 @default.
• W4379285619 creator A5030577122 @default.
• W4379285619 creator A5038041478 @default.
• W4379285619 creator A5038366277 @default.
• W4379285619 creator A5041444234 @default.
• W4379285619 creator A5067172804 @default.
• W4379285619 creator A5070418550 @default.
• W4379285619 creator A5071827538 @default.
• W4379285619 creator A5073849119 @default.
• W4379285619 creator A5082511680 @default.
• W4379285619 creator A5083074248 @default.
• W4379285619 creator A5084384049 @default.
• W4379285619 date "2023-06-01" @default.
• W4379285619 modified "2023-09-25" @default.
• W4379285619 title "A randomized phase II clinical trial of talazoparib maintenance therapy in patients with triple-negative breast cancer who showed platinum-sensitivity on first- or second-line platinum-based chemotherapy: KCSG BR21-10." @default.
• W4379285619 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps1132" @default.
• W4379285619 hasPublicationYear "2023" @default.
• W4379285619 type Work @default.
• W4379285619 citedByCount "0" @default.
• W4379285619 crossrefType "journal-article" @default.
• W4379285619 hasAuthorship W4379285619A5013612802 @default.
• W4379285619 hasAuthorship W4379285619A5019945009 @default.
• W4379285619 hasAuthorship W4379285619A5021046796 @default.
• W4379285619 hasAuthorship W4379285619A5023107984 @default.
• W4379285619 hasAuthorship W4379285619A5025054615 @default.
• W4379285619 hasAuthorship W4379285619A5030577122 @default.
• W4379285619 hasAuthorship W4379285619A5038041478 @default.
• W4379285619 hasAuthorship W4379285619A5038366277 @default.
• W4379285619 hasAuthorship W4379285619A5041444234 @default.
• W4379285619 hasAuthorship W4379285619A5067172804 @default.
• W4379285619 hasAuthorship W4379285619A5070418550 @default.
• W4379285619 hasAuthorship W4379285619A5071827538 @default.
• W4379285619 hasAuthorship W4379285619A5073849119 @default.
• W4379285619 hasAuthorship W4379285619A5082511680 @default.
• W4379285619 hasAuthorship W4379285619A5083074248 @default.
• W4379285619 hasAuthorship W4379285619A5084384049 @default.
• W4379285619 hasConcept C104317684 @default.
• W4379285619 hasConcept C121608353 @default.
• W4379285619 hasConcept C126322002 @default.
• W4379285619 hasConcept C141071460 @default.
• W4379285619 hasConcept C142724271 @default.
• W4379285619 hasConcept C143998085 @default.
• W4379285619 hasConcept C182979987 @default.
• W4379285619 hasConcept C204787440 @default.
• W4379285619 hasConcept C27081682 @default.
• W4379285619 hasConcept C2775930923 @default.
• W4379285619 hasConcept C2776694085 @default.
• W4379285619 hasConcept C2779138821 @default.
• W4379285619 hasConcept C2780110267 @default.
• W4379285619 hasConcept C2780194787 @default.
• W4379285619 hasConcept C31760486 @default.
• W4379285619 hasConcept C530470458 @default.
• W4379285619 hasConcept C535046627 @default.
• W4379285619 hasConcept C55493867 @default.
• W4379285619 hasConcept C71924100 @default.
• W4379285619 hasConcept C82381507 @default.
• W4379285619 hasConcept C86803240 @default.
• W4379285619 hasConceptScore W4379285619C104317684 @default.
• W4379285619 hasConceptScore W4379285619C121608353 @default.
• W4379285619 hasConceptScore W4379285619C126322002 @default.
• W4379285619 hasConceptScore W4379285619C141071460 @default.
• W4379285619 hasConceptScore W4379285619C142724271 @default.
• W4379285619 hasConceptScore W4379285619C143998085 @default.
• W4379285619 hasConceptScore W4379285619C182979987 @default.
• W4379285619 hasConceptScore W4379285619C204787440 @default.
• W4379285619 hasConceptScore W4379285619C27081682 @default.
• W4379285619 hasConceptScore W4379285619C2775930923 @default.
• W4379285619 hasConceptScore W4379285619C2776694085 @default.
• W4379285619 hasConceptScore W4379285619C2779138821 @default.
• W4379285619 hasConceptScore W4379285619C2780110267 @default.
• W4379285619 hasConceptScore W4379285619C2780194787 @default.
• W4379285619 hasConceptScore W4379285619C31760486 @default.
• W4379285619 hasConceptScore W4379285619C530470458 @default.
• W4379285619 hasConceptScore W4379285619C535046627 @default.
• W4379285619 hasConceptScore W4379285619C55493867 @default.
• W4379285619 hasConceptScore W4379285619C71924100 @default.
• W4379285619 hasConceptScore W4379285619C82381507 @default.
• W4379285619 hasConceptScore W4379285619C86803240 @default.
• W4379285619 hasFunder F4320307765 @default.
• W4379285619 hasIssue "16_suppl" @default.
• W4379285619 hasLocation W43792856191 @default.
• W4379285619 hasOpenAccess W4379285619 @default.
• W4379285619 hasPrimaryLocation W43792856191 @default.
• W4379285619 hasRelatedWork W2034849620 @default.
• W4379285619 hasRelatedWork W2046474315 @default.
• W4379285619 hasRelatedWork W2092771806 @default.
• W4379285619 hasRelatedWork W2245189862 @default.
• W4379285619 hasRelatedWork W2317787856 @default.
• W4379285619 hasRelatedWork W2418436192 @default.
• W4379285619 hasRelatedWork W2534174115 @default.
• W4379285619 hasRelatedWork W2782589310 @default.
• W4379285619 hasRelatedWork W3133785871 @default.

• next